Corporate Travel Management (ASX: CTD) – CTD Files 2026 Annual Report
Corporate Travel Management's FY2025 annual report reveals material accounting irregularities in the company's UK subsidiary that resulted in...
ASX Announcements
Corporate Travel Management (ASX: CTD) – Corporate Travel Management Presentation 51
Corporate Travel Management has identified and quantified significant accounting and operational issues in its UK business that resulted in customer...
Corporate Travel Management (ASX: CTD) – Files H1 2026 Half Year Accounts
Corporate Travel Management's half-year result to 31 December 2025 delivered a substantial uplift in profitability, with profit before tax climbing...
Corporate Travel Management (ASX: CTD) – FY25 and H1 2026 Results
Corporate Travel Management Limited reported a net loss after tax of $346.7 million for FY25, a result primarily driven by goodwill impairments of...
Corporate Travel Management (ASX: CTD) – Files Preliminary Final Report 3
Corporate Travel Management Limited reported a dramatic turnaround in FY25, swinging to a loss of $348.5 million after reporting a profit of $19.0...
Clinuvel Pharmaceuticals (ASX: CUV) – Clinuvel considers Nasdaq listing and ASX delisting
CLINUVEL Pharmaceuticals has announced that its Board of Directors is considering a significant restructuring that would see the company transition...
Clinuvel Pharmaceuticals (ASX: CUV) – Clinuvel Files Investor Presentation 12
Clinuvel Pharmaceuticals has launched its investor presentation for the financial year ended 30 June 2026, with a stated focus on U.S. expansion...
Clinuvel Pharmaceuticals (ASX: CUV) – Decade of profitability fuels U.S. expansion
Clinuvel Pharmaceuticals has delivered its tenth consecutive annual profit, capping off a decade of commercial operations that has generated a 31%...
Clinuvel Pharmaceuticals (ASX: CUV) – Files 2026 Annual Report and Appendix 4E
Clinuvel Pharmaceuticals reported a year ending 30 June 2026 with revenues declining 1 percent to A$94.0 million and net profit falling 6 percent to...
Objective Corporation (ASX: OCL) – Objective Files FY2026 Investor Presentation
Objective Corporation has delivered solid full-year results for FY2026, with revenue rising 9 percent to $135 million and adjusted EBITDA climbing...